Esperion Therapeutics Inc., of Ann Arbor, Mich. reported that it raised net proceeds of $91.6 million in a now-closed follow-on offering. The company sold about 4.9 million shares at $20 each, with underwriters exercising in full their option to buy 637,500 shares. Esperion intends to use the financing to fund continued development of ETC-1002, a small-molecule cholesterol drug that inhibits ATP citrate lyase while activating AMPK, through completion of an anticipated phase III program.)